Jakura, referred to as tofacitinib, in its 5mg dosage, represents a significant breakthrough in the control of rheumatoid arthritis (RA). This oral medication, a targeted Janus kinase (JAK) inhibitor, works by blocking the signaling pathways that contribute to inflammation and joint damage characteristic of RA. Unlike traditional disease-modifying